CAR-T细胞治疗的现状与临床应用前景  

Current situation and clinical application prospect of CAR-T cell therapy

作　　者：郑晓[1] 蒋敬庭[1] ZHENG Xiao;JIANG Jingting(Department of Tumor Biological Treatment,the Third Affiliated Hospital of Soochow University,Jiangsu Engineering Research Center for Tumor Immunotherapy,Changzhou 213003,China)

机构地区：[1]苏州大学附属第三医院肿瘤生物诊疗中心江苏省肿瘤免疫治疗工程技术研究中心,江苏常州213003

出　　处：《临床肿瘤学杂志》2018年第7期655-660,共6页Chinese Clinical Oncology

基　　金：国家科技支撑计划(2015BAI12B12);国家自然科学基金面上项目(31570877;31570908);常州市应用基础研究项目(CJ20160021);江苏省检验医学重点实验室开放基金(JSKLM-2014-003)

摘　　要：嵌合抗原受体T细胞(CAR-T)疗法是肿瘤过继免疫治疗的新手段。CAR-T细胞疗法治疗B细胞急性淋巴细胞白血病(B-ALL)的完全缓解率高达90%。然而,目前CAR-T细胞疗法在血液肿瘤的治疗过程中尚存在脱靶效应、毒副作用、体内持续时间短与复发率高等问题。此外,在CAR-T细胞治疗实体瘤方面的安全性和有效性虽已得到证实,但疗效还有待提高。本文对近年来CAR-T细胞治疗的研究进展及该领域中亟需解决的问题作一分析与展望。Chimeric antigen receptor T cells(CAR-T)therapy is a new method of tumor immunotherapy.The complete response rate of CAR-T cell therapy for B cell acute lymphoblastic leukemia(B-ALL)is as high as 90%.However,there are some problems of CAR-T cell therapy in the treatment of blood tumor,such as off-target activity,toxic side effect,short duration of the body and high recurrence rate.In addition,the safety and efficacy of CAR-T cells in the treatment of solid tumors have been confirmed,but the efficacy remains to be improved.In this paper,the research progression of CAR-T cell therapy in recent years and the urgent problems in this field are analyzed and prospected.

关 键 词：肿瘤 嵌合抗原受体T细胞 肿瘤免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]